Form 4: Jasper Therapeutics COO Exercises and Sells Shares Under 10b5-1 Trading Plan

Jeet Mahal, COO of Jasper Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Jeet Mahal, the Chief Operating Officer of Jasper Therapeutics, Inc., executed a transaction involving the company's stock on June 12, 2024.
• Mahal exercised options to acquire 900 shares of Voting Common Stock at a price of $7.10 per share.
• Simultaneously, Mahal sold 900 shares of Voting Common Stock at a weighted average price of $24.155, with prices ranging from $23.975 to $24.555.
• These transactions were conducted under a pre-existing Rule 10b5-1 trading plan adopted on March 15, 2023.
• Following these transactions, Mahal directly owns 25,009 shares of Voting Common Stock and holds options for 15,572 shares.
• A Power of Attorney document was also filed, granting Ronald Martell and Herb Cross the authority to execute securities filings on Mahal's behalf.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock transactions by an executive. It doesn't contain information that would significantly impact sentiment positively or negatively.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Future Outlook

There is no specific future outlook provided in this document.

Industry Context

This filing is a routine disclosure related to insider trading activity. It is common for executives to utilize 10b5-1 trading plans to manage their stock transactions and avoid potential accusations of trading on non-public information. The filing itself doesn't provide insight into the company's overall performance or strategy.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.

Key Dates